NASDAQ:OTIC

Otonomy (OTIC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.0085
$0.0085
50-Day Range
$0.01
$0.12
52-Week Range
$0.01
$2.54
Volume
N/A
Average Volume
937,525 shs
Market Capitalization
$582,479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OTIC stock logo

About Otonomy Stock (NASDAQ:OTIC)

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

OTIC Stock News Headlines

Otonomy, Inc.: Otonomy Provides Corporate Update
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Otonomy Provides Corporate Update
5 Investors Betting Big on Otonomy (OTIC) Stock
Why Is Otonomy (OTIC) Stock Up 97% Today?
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Profitability

Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
67,780,000
Market Cap
$582,479.50
Optionable
Optionable
Beta
1.54
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Paul E. Cayer
    President, CFO, Secretary & Chief Business Officer
  • Anna Stepannenko
    Vice President -Technical operations
  • Fabrice Piu
    Vice President-Research & Preclinical Development
  • David Skarinsky
    Vice President-Clinical
  • Jeffery J. Anderson
    Vice President-Clinical Sciences

OTIC Stock Analysis - Frequently Asked Questions

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) announced its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). During the same period last year, the firm earned ($0.22) earnings per share.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

This page (NASDAQ:OTIC) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners